Latest News on ILMN

Financial News Based On Company


Advertisement
Advertisement

Element AVITI Demonstrates Higher Quality Scores Than Illumina NovaSeq Across Diverse Applications

https://bioengineer.org/element-aviti-demonstrates-higher-quality-scores-than-illumina-novaseq-across-diverse-applications/
A cross-platform benchmarking study compared the Element BioSciences AVITI and Illumina NovaSeq 6000 sequencing platforms across whole-genome, whole-exome, and targeted panel sequencing applications. The AVITI platform consistently showed higher base quality scores (Q30) across all applications. While whole-genome sequencing on AVITI demonstrated superior depth, coverage, and variant detection, whole-exome and targeted panel sequencing yielded comparable downstream performance between the two platforms.

Illumina Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/illumina-inc-stock-outperforms-competitors-on-strong-trading-day-5ff37893-8c82a7bb3a4c?mod=goog_fin_scmw
Illumina Inc. (ILMN) saw its stock rise by 3.65% to $210.01 on Wednesday, outperforming the broader market which experienced a downturn. The S&P 500 Index fell 0.23%, and the Dow Jones Industrial Average dropped 1.11% on the same trading day. This marked the second consecutive day of gains for Illumina's stock.

Illumina, Inc. (ILMN) Selected for Singapore Study of Around 450,000 People

https://www.tradingview.com/news/tradingview:79cd3cdb6181a:0-illumina-inc-ilmn-selected-for-singapore-study-of-around-450-000-people/
Illumina, Inc. (ILMN) has been chosen to provide whole-genome sequencing services for Singapore's SG-INSIGHT study, which is expected to include approximately 450,000 participants. This selection follows an international competitive tender and expands Illumina's existing precision-medicine work in Singapore, building on a previous engagement. The release did not disclose any contract value or financial terms related to this new selection.

A Singapore study could read the genetic code of about 450,000 people

https://www.stocktitan.net/news/ILMN/illumina-selected-to-help-bring-precision-medicine-into-everyday-f7jc436rzh8l.html
Illumina has been selected to provide whole-genome sequencing services for Singapore's SG-INSIGHT precision medicine study, part of the National Precision Medicine programme's Phase III. This study aims to include approximately 450,000 individuals, connecting genomic and health data to inform preventive care and introduce genetic screening into public healthcare. Illumina will perform sequencing at its local genomics facility in Singapore, building on its prior support for Phase II which covered over 100,000 genomes.

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=29346
Illumina has been chosen to provide whole-genome sequencing services for Singapore's SG-INSIGHT study, part of the National Precision Medicine (NPM) programme. This study aims to include approximately 450,000 Singapore residents to generate evidence from genomic and health data, informing preventive healthcare approaches. By integrating genomic information with real-world health data, SG-INSIGHT seeks to enhance understanding of diseases and treatment responses, ultimately moving healthcare toward more precise interventions tailored to individuals.
Advertisement

Illumina Inc. stock underperforms Monday when compared to competitors

https://www.marketwatch.com/data-news/illumina-inc-stock-underperforms-monday-when-compared-to-competitors-a63da0cc-ac6f63fc06a4
Illumina Inc. (ILMN) stock decreased by 3.99% to $226.58 on Monday, experiencing its second consecutive day of losses. This occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index declined. The article highlights Illumina's underperformance relative to its competitors.

What Sent Illumina Stock Lower?

https://www.trefis.com/stock/ilmn/articles/621870/what-sent-illumina-stock-lower/2026-11-01
Illumina's stock (ILMN) dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year outlook. The decline was attributed to missing revenue estimates and the broader market selloff in AI stocks, although the healthcare sector generally rose that day. The article notes that while other peers also fell, Illumina's drop was significantly larger, suggesting company-specific factors were at play.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026

https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=29326
Illumina reported strong financial results for the third quarter of fiscal year 2026, with reported revenue up 4.2% year-over-year to $1.13 billion. The company raised its full-year revenue and earnings guidance, driven by healthy clinical demand and robust NovaSeq X placements. Illumina's CEO, Jacob Thaysen, highlighted continued innovation broadening the value of the Illumina ecosystem and laying the foundation for AI to transform understanding of human biology and improve patient outcomes.

Illumina Stock Slumps Despite Full-Year Guidance Raise, Solid Q3 Results

https://www.genomeweb.com/company/illumina/gnw-illumina-q3-earnings-results-20261030/
Illumina's stock experienced a decline despite the company announcing solid third-quarter financial results and raising its full-year guidance. The article highlights the discrepancy between the company's positive financial performance and the market's negative reaction. It was published on October 30, 2026.

Illumina, Inc. (ILMN) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ILMN/seasonality/
This article provides a seasonal returns chart for Illumina, Inc. (ILMN), displaying average monthly price returns from 2016 to 2026. It includes current stock price information and links to other financial data such as news, research, and historical data.
Advertisement

Illumina Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62723601/illumina-q3-2026-earnings-call-transcript
Illumina reported strong Q3 2026 financial results with $1.17 billion in revenue, up 4.7% year-over-year on a rest-of-world organic basis, driven by clinical sequencing demand and NovaSeq X placements. The company raised its full-year guidance, anticipating revenue between $4.64 billion and $4.66 billion, and highlighted strategic initiatives like the Billion Cell Atlas and BioInsight platform for future growth in AI-ready datasets and multi-omics. Management expressed confidence in achieving long-term financial targets, citing robust market conditions, particularly in the clinical sector, and ongoing innovation as key growth drivers.

Illumina shares tumble 12% despite earnings beat on China woes

https://finance.yahoo.com/markets/stocks/articles/illumina-shares-tumble-12-despite-215910139.html
Illumina Inc. (NASDAQ:ILMN) reported third-quarter results that surpassed analyst expectations for both adjusted EPS and revenue. Despite this earnings beat and a raised full-year guidance, the company's shares fell 12% in after-hours trading due to a decline in China revenue, which weighed heavily on investor sentiment. CEO Jacob Thaysen noted healthy clinical demand and strong NovaSeq X placements as key drivers for the positive results.

Illumina Inc. stock underperforms Wednesday when compared to competitors despite daily gains

https://www.marketwatch.com/data-news/illumina-inc-stock-underperforms-wednesday-when-compared-to-competitors-despite-daily-gains-751c4167-cecf8a7dcb1f?mod=goog_fin_scmw
Illumina Inc. (ILMN) stock gained 3.33% on Wednesday, reaching $288.79, in a positive trading session where both the S&P 500 and Dow Jones Industrial Average also rose. Despite this daily gain and being its fourth consecutive day of increases, the stock underperformed when compared to some of its competitors.

Illumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

https://sg.finance.yahoo.com/news/illumina-ilmn-q3-earnings-horizon-121502562.html
Wall Street analysts predict Illumina (ILMN) will report Q3 earnings of $1.36 per share, a 1.5% increase year-over-year, with revenues forecasted at $1.14 billion, up 4.9%. The consensus EPS estimate has remained stable over the past 30 days. The article details specific revenue estimates for various segments like consumables, instruments, sequencing, and microarrays, indicating expected changes from the prior-year quarter.

Thinking Out of the ‘Box’: NGS Platform Makers Eye Data Biz Amidst AI Biology Gold Rush

https://www.genomeweb.com/technology/sequencing/gnw-ngs-platform-makers-data-business-20261028/
Next-generation sequencing (NGS) platform manufacturers are reportedly looking beyond their traditional hardware business to capitalize on the growing demand for data in the artificial intelligence (AI) biology sector. This strategic shift aims to leverage the extensive genomic data generated by their platforms. The move signifies an evolving landscape in the genomics industry, where data is becoming as valuable as the sequencing technology itself.
Advertisement

BlackRock reports sole voting power over 12M Illumina (ILMN) shares in an amended stake report.

https://www.stocktitan.net/sec-filings/ILMN/schedule-13g-a-illumina-inc-amended-passive-investment-disclosure-f6d1e5a3f8d0.html
BlackRock, Inc. has filed an amended report (SCHEDULE 13G/A) disclosing a beneficial ownership stake of 8.9% in Illumina, Inc. (ILMN) common stock, totaling 13,479,370 shares as of September 30, 2026. The report indicates that BlackRock holds sole voting power over 11,956,205 shares and sole dispositive power over all 13,479,370 shares, with no shared voting or dispositive power. This filing reflects the holdings of specific BlackRock business units and affiliates.

Illumina To Webcast Upcoming Investor Conference

https://www.streetinsider.com/PRNewswire/Illumina+To+Webcast+Upcoming+Investor+Conference/27241542.html
Illumina, Inc. announced that its management team will participate in the Jefferies Global Healthcare Conference on November 17, 2026, with a fireside chat scheduled for 02:30 AM PT (10:30 AM GMT). A webcast of the event will be available on Illumina's investor relations website, with a replay archived for at least 30 days. The company, a global leader in DNA sequencing, aims to improve human health through genomic innovation.

Illumina Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/illumina-inc-stock-outperforms-competitors-on-strong-trading-day-e5a35cf6-a04125bfc501
Illumina Inc. (ILMN) stock rallied 3.11% to $279.47, outperforming the broader market on a strong trading day. The S&P 500 Index rose 0.60% and the Dow Jones Industrial Average rose 0.03%. This marks the third consecutive day of gains for Illumina's stock.

Here’s How Much You Would Have Made Owning Illumina Stock In The Last 20 Years

https://www.benzinga.com/news/26/10/62566927/here-s-how-much-you-would-have-made-owning-illumina-stock-last-20-years
Illumina (NASDAQ: ILMN) has outperformed the market over the past 20 years, generating an average annual return of 13.52%. An investment of $100 in ILMN stock two decades ago would now be worth $1,250.85, highlighting the significant impact of compounded returns over time.

Illumina, Inc. Estimates – NASDAQ:ILMN

https://www.tradingview.com/symbols/NASDAQ-ILMN/financials-estimates/
This page provides financial estimates for Illumina, Inc. (NASDAQ:ILMN), covering reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time. The content explicitly states that it is not investment advice.
Advertisement

Illumina stock may move 9.3% on earnings release

https://www.investing.com/news/stock-market-news/illumina-stock-may-move-93-on-earnings-release-93CH-4966690
Illumina Inc. (ILMN) stock is predicted by options data to move 9.3% following its upcoming earnings release on October 29. Historically, the company's stock price has exceeded the options-implied move in six of the past eight earnings announcements. The article provides examples of past implied versus actual stock movements.

ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance

https://www.tradingview.com/news/zacks:941d956b8094b:0-ilmn-q3-earnings-preview-strong-clinical-demand-may-lift-performance/
Illumina (ILMN) is expected to announce its Q3 2026 earnings on October 29, with estimates suggesting a 5% revenue increase and a 3% EPS rise year-over-year, driven by strong clinical market demand and NovaSeq X platform placements. The company's recent innovations and the Billion Cell Atlas program are also anticipated to contribute to growth, despite some pressure in research and academic markets. Illumina currently holds a Zacks Rank #2 with a positive Earnings ESP of +9.16%, indicating a higher chance of beating estimates.

Illumina Jumps 5.4% Amid Sector-Wide Rally

https://news.alphastreet.com/illumina-jumps-5-4-amid-sector-wide-rally/
Illumina's stock surged 5.4% Wednesday, closing at $282.31, as a broad sector-wide rally lifted diagnostics and research stocks. This jump reflects coordinated buying across the sector rather than company-specific news, with peers like Danaher and Medpace Holdings also seeing significant gains. Analyst sentiment remains positive, with recent target raises, indicating a constructive view on Illumina amidst reevaluated valuations in the healthcare landscape.

Illumina's Stock Has Run Ahead Of Its Q3 Step-Down, Raising The Stakes On Clinical Demand

https://finviz.com/news/406099/illuminas-stock-has-run-ahead-of-its-q3-step-down-raising-the-stakes-on-clinical-demand
Illumina's stock has rallied significantly despite management signaling a slower third quarter. The key focus for the upcoming earnings report will be the sustained demand in clinical consumables, which saw growth cool slightly last quarter. Analysts are also watching research and applied markets, margins, and updates on newer growth drivers to see if the company can justify its stock's recent performance and maintain its long-term growth trajectory.

Illumina Shares Rise as New BioInsight Software Launch Appears to Lift Sentiment

https://www.quiverquant.com/news/Illumina+Shares+Rise+as+New+BioInsight+Software+Launch+Appears+to+Lift+Sentiment
Illumina's shares (ILMN) rose 6.3% following the announcement of new early-access software tools for its BioInsight Platform, focusing on AI-driven genomic analysis and workflow automation. This product launch, introduced at a major industry event, also reflects continued investor confidence in the company's turnaround and upcoming Q3 results on October 29, 2026.
Advertisement

Illumina Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/illumina-inc-stock-outperforms-competitors-on-strong-trading-day-0afa8644-6b0244a4b168
Illumina Inc. (ILMN) stock saw a significant gain of 5.57%, closing at $282.86 on Wednesday. This performance outpaced broader market indices like the S&P 500 and Dow Jones Industrial Average, marking the stock's third consecutive day of increases.

Illumina Jumps 5.4% Amid Sector-Wide Rally

https://news.alphastreet.com/illumina-jumps-5-4-amid-sector-wide-rally/amp/
Illumina (ILMN) saw its stock surge by 5.4% as a broad rally lifted diagnostics and research stocks across the sector. This increase appears to be driven by coordinated buying and broader investor sentiment rather than company-specific news, with peers like Danaher (DHR) and Medpace Holdings (MEDP) also experiencing significant gains. Recent analyst activity has been positive, and investors are advised to monitor whether this sector-wide strength will be sustained.

Illumina launches three AI genomic analysis tools in early access By Investing.com

https://ca.investing.com/news/stock-market-news/illumina-launches-three-ai-genomic-analysis-tools-in-early-access-93CH-4893815
Illumina Inc. has launched three new AI-powered genomic analysis tools on its BioInsight Platform, now available in early access. These tools, including Workflow Orchestrator, DRAGEN Ultra, and Learning Cohorts, are designed to automate genomic data analysis, prioritize genetic variants using AI, and enable researchers to analyze diverse datasets. The announcement was made at the American Society of Human Genetics annual meeting, highlighting Illumina's commitment to enhancing genomic research efficiency and discovery.

Illumina launches AI-powered tools for faster, scalable genomic research and discovery

https://pluang.com/en/news-feed/platform-bioinsight-illimina-percepat-penemuan-dengan-software-baru
Illumina has introduced new AI-driven tools—DRAGEN Ultra, Workflow Orchestrator, and Learning Cohorts—on its BioInsight Platform to accelerate genomic research. These early-access capabilities aim to automate sequencing, prioritize genetic variants using AI, and facilitate the analysis of large genomic datasets. The innovation seeks to help laboratories scale operations efficiently and enhance discovery in genetics and disease research.

Illumina, Inc. (ILMN) Launches Early-Access AI Genomics Tools

https://www.tradingview.com/news/tradingview:d1537557a26c2:0-illumina-inc-ilmn-launches-early-access-ai-genomics-tools/
Illumina (ILMN) has introduced three early-access AI capabilities—DRAGEN Ultra, Workflow Orchestrator, and Learning Cohorts—on its BioInsight Platform. These tools are designed to accelerate the analysis and discovery of sequencing data, aiming to expand Illumina's software and AI strategy. The company hopes these additions will drive platform adoption, increase data usage, and potentially lead to future revenue growth.
Advertisement

Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery

https://www.prnewswire.com/news-releases/illumina-bioinsight-platform-expands-with-new-software-to-accelerate-the-path-from-sequencing-to-discovery-302914943.html
Illumina has introduced three new early-access capabilities for its BioInsight Platform: Workflow Orchestrator, DRAGEN Ultra, and Learning Cohorts. These tools are designed to streamline and accelerate the process from sequencing data to scientific discovery by automating informatics processes, utilizing AI for variant prioritization, and enabling the investigation of large genomic datasets for patterns. The expansion aims to provide researchers with consistent, scalable, and reproducible workflows to advance genomic and multiomic research.

Illumina adds three tools to BioInsight genomics platform

https://www.streetinsider.com/Corporate+News/Illumina+adds+three+tools+to+BioInsight+genomics+platform/27214282.html
Illumina, Inc. (NASDAQ: ILMN) has unveiled three new early-access software capabilities for its BioInsight Platform at the American Society of Human Genetics annual meeting. These additions, Workflow Orchestrator, DRAGEN Ultra, and BioInsight Platform Learning Cohorts, aim to enhance genomic operations by automating workflows, utilizing AI for variant prioritization, and enabling researchers to build and analyze private genomic cohorts. The company states that DRAGEN Ultra's dnaAI model has shown significant improvements in identifying disease associations and ranking known disease-associated variants.

Illumina launches three AI genomic analysis tools in early access By Investing.com

https://uk.investing.com/news/stock-market-news/illumina-launches-three-ai-genomic-analysis-tools-in-early-access-93CH-4922902
Illumina Inc. has launched three new AI-powered software capabilities on its BioInsight Platform for early access customers. These tools, including BioInsight Platform Workflow Orchestrator, DRAGEN Ultra, and BioInsight Platform Learning Cohorts, are designed to automate genomic data analysis, prioritize genetic variants using AI, and enable researchers to analyze diverse datasets across private sample collections. The announcement was made at the American Society of Human Genetics annual meeting, highlighting the company's focus on enhancing research workflows and identifying critical findings in genomic studies.

Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery

https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=29271
Illumina has introduced three new early-access capabilities for its BioInsight Platform: DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts. These tools aim to automate end-to-end informatics processes, streamline genomic analysis, and enable researchers to build private data lakes for advanced scientific and clinical insights. The new software incorporates AI-driven approaches to accelerate the path from sequencing data to discovery by prioritizing variants and revealing patterns across large genomic and multiomic datasets.

Illumina To Webcast Upcoming Investor Conference

https://www.tradingview.com/news/prnewswire:2217f8b9c3bab:0-illumina-to-webcast-upcoming-investor-conference/
Illumina, Inc. announced its management team will participate in the UBS Global Healthcare Conference on November 10, 2026, with a fireside chat scheduled for 07:15 AM PT (10:15 AM ET). A live webcast and subsequent replay will be available on the company's investor relations website. The company aims to improve human health through genomic innovation, specializing in DNA sequencing and array-based technologies.
Advertisement

Canaccord raises target for Illumina stock from USD 205.00 to USD 300.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/canaccord-raises-target-for-illumina-stock-from-usd-205-00-to-usd-300-00/70376819
Canaccord Genuity has increased its price target for Illumina stock from $205.00 to $300.00, while maintaining a Hold rating. This target revision follows Illumina's second-quarter 2026 revenue of $1.16 billion and adjusted earnings per share of $1.31, both exceeding consensus estimates. The company is set to report its third-quarter 2026 results on October 29, 2026.

BofA raises Illumina stock target to USD 168.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/bofa-raises-illumina-stock-target-to-usd-168-00/70349256
BofA has increased its price target for Illumina (ILMN) stock from USD 140.00 to USD 168.00, though maintaining an "Underperform" rating. The stock closed at USD 262.54 on October 16, 2026, and Illumina is set to release its third-quarter 2026 results on October 29, 2026. The new target is significantly below the current trading price, indicating a cautious outlook despite the raised target.

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

https://finance.yahoo.com/markets/stocks/articles/illumina-ilmn-beat-estimates-again-151006187.html
Illumina (ILMN) is predicted to beat its upcoming earnings estimates, continuing a trend of exceeding expectations. The company has a positive Zacks Earnings ESP of +9.16% and a Zacks Rank #2 (Buy), indicating a high probability of a positive surprise. The next earnings report is expected on October 29, 2026.

Illumina Inc. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/illumina-inc-stock-underperforms-thursday-when-compared-to-competitors-20806e19-0673aa1c5145?mod=mw_quote_news
Illumina Inc. (ILMN) saw its stock decline by 1.41% on Thursday, closing at $267.93, despite a positive trading day for the broader market with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock is currently 13.39% below its 52-week high of $309.35, which was reached on October 6th.

TD Cowen lifts target for Illumina stock to USD 270.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/td-cowen-lifts-target-for-illumina-stock-to-usd-270-00/70331303
TD Cowen has raised its price target for Illumina (ILMN) stock to USD 270.00 from USD 210.00, while maintaining a Hold rating. This new target is slightly higher than the stock's recent Nasdaq price of USD 267.50. Illumina is set to release its fiscal third-quarter 2026 earnings on October 29, 2026, with expected diluted earnings per share of USD 1.36.
Advertisement

$100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today

https://www.benzinga.com/news/26/10/62371344/100-invested-illumina-15-years-ago-would-be-worth-much-today
This article examines the return on a $100 investment in Illumina (NASDAQ: ILMN) made 15 years ago. Over this period, Illumina outperformed the market, yielding an average annual return of 16.89%. The initial $100 investment would now be worth $1,066.70.

Illumina 5-Base DNA Prep with Enzymatic Fragmentation

https://www.illumina.com/science/genomics-research/articles/illumina-5-base-dna-prep-with-enzymatic-fragmentation.html
This article evaluates the use of NEBNext UltraShear enzymatic fragmentation as an alternative to Covaris mechanical shearing for Illumina 5-Base DNA Prep. The study, led by Dr. Christian Pflueger, demonstrates that enzymatic fragmentation produces comparable library profiles and preserves global methylation levels while simplifying the workflow by eliminating the need for dedicated mechanical shearing instrumentation and post-fragmentation cleanup. Although some minor regional methylation differences were observed, the overall performance for DNA methylation profiling and sequencing metrics was robust.

Illumina Consolidates Data Analysis Products Into New Platform, Pricing Model

https://www.genomeweb.com/company/illumina/gnw-illumina-bioinsight-platform-ai-data-20261014/
Illumina has launched a new platform called BioInsight to consolidate its data analysis products. This move includes a new pricing model for these integrated tools. The platform aims to streamline data analysis for users.

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

https://www.prnewswire.com/news-releases/illumina-launches-bioinsight-platform-its-first-unified-software-environment-to-help-accelerate-genomic-and-multiomic-breakthroughs-302907972.html
Illumina has launched the BioInsight Platform, a unified software environment designed to accelerate genomic and multiomic research by integrating advanced analysis, purpose-built AI, and curated biological data. The platform aims to help researchers efficiently convert complex data into actionable insights and includes an updated version of DRAGEN for flexible secondary analysis. This initiative addresses the challenges of large-scale genomic datasets, leveraging AI and curated data to advance drug discovery and disease understanding.

Illumina launches BioInsight Platform for genomic data analysis

https://www.streetinsider.com/Corporate+News/Illumina+launches+BioInsight+Platform+for+genomic+data+analysis/27185032.html
Illumina (NASDAQ: ILMN) has introduced its BioInsight Platform, a unified software environment designed for genomic and multiomic data analysis. The platform integrates various analysis applications, AI tools, and data resources, including the updated DRAGEN v4.6 and the BioInsight AI Lab, which features the new SpliceAI2 model for rare disease research. Illumina is also shifting to a usage-based BioInsight Credits pricing model and will showcase the platform at the American Society for Human Genetics annual meeting.
Advertisement

Illumina, Inc. (ILMN) Launches BioInsight Platform With DRAGEN v4.6

https://www.tradingview.com/news/tradingview:acf9aab4ebb2b:0-illumina-inc-ilmn-launches-bioinsight-platform-with-dragen-v4-6/
Illumina has launched its BioInsight Platform, integrating AI, software, and curated data, and including the DRAGEN v4.6 with expanded deployment options. This move signifies Illumina's focus on higher-margin software and AI to monetize its sequencing and multiomics capabilities. The platform aims to increase user adoption and recurring revenue through flexible consumption pricing and broader accessibility.

Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements

https://www.tradingview.com/news/tradingview:273e3da599402:0-illumina-launches-1-0-billion-unsecured-commercial-paper-program-signs-dealer-agreements/
Illumina has established an unsecured commercial paper program of up to $1.0 billion to enhance its liquidity and financial flexibility. This program allows the company to issue short-term notes with maturities up to 397 days for general corporate purposes. Multiple commercial paper dealers and a national bank will facilitate the program, though no notes were outstanding as of the filing date.

Illumina establishes $1B commercial paper program

https://www.streetinsider.com/Corporate+News/Illumina+establishes+%241B+commercial+paper+program/27181729.html
Illumina, Inc. (NASDAQ: ILMN) has established an unsecured commercial paper program allowing it to issue up to $1.0 billion in short-term notes. These notes will mature within 397 days and the proceeds are intended for general corporate purposes. No notes have been issued under the program as of the filing date.

Illumina Inc. stock underperforms Tuesday when compared to competitors

https://www.marketwatch.com/data-news/illumina-inc-stock-underperforms-tuesday-when-compared-to-competitors-c9e3cb2c-3852e17db793?mod=goog_fin_scmw
Illumina Inc. (ILMN) stock dropped 1.99% on Tuesday, closing at $271.18, amidst a general downturn in the stock market. This marked the second consecutive day of losses for the company, as the S&P 500 Index also fell 0.02% and the Dow Jones Industrial Average declined 0.35%.

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

https://www.illumina.com/company/news-center/press-releases/2026/29256.html
Illumina has launched the BioInsight Platform, a unified software environment designed to accelerate genomic and multiomic research by converting complex data into actionable biological insights. The platform integrates Illumina's analysis applications, AI innovations like the new SpliceAI2 model, and curated data resources. It also includes DRAGEN v4.6, which offers expanded deployment options for high-performance secondary analysis, and transitions to a usage-based credit model for greater flexibility.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement